Background: Hodgkin disease (HL) is curable disease in up to 80% of patients, but for the remaining relapse/refractory patients no standard salvage therapy exists. Brentuximab vedotin comprises an anti CD30 antibody conjugated by a protease-cleavable linker to a microtubule-disrupting agent. Aims: The aim of the study is to evaluate the outcome of patients with relapse/refractory form of HL, who received Brentuximab vedotin. Methods: In our Institute 21 patients with HL were treated, from 2015 till 2018 years. 17 (81%) patients had a primary-resistant form, four (19%) patients had relapse of the disease. The average age was 34.5 years (from 20 to 69 years), the average number of courses of therapy is 5.38 (from 3 to 8 courses). The mean follow-up period was 17.9 months (from 4.1 to 38.1 months). Results: We have analyzed the survival of patients who received treatment. 21 patients who entered the study at the time of collection of information, 15 (71.4%) patients were alive. Median survival was 33.2 months. The standard error (SE) is 3.3 months, with 95% CI (26.8 -39.6). Among patients with a primary resistant form, 13 (76.5%) patients were alive, with a median survival of 28.1 months, a SE of 2.3 months of 95% ). Among patients with a non-primary resistant form, two (50%) patients were alive, while the median survival was 9.1 months, SE 2.4 months 95% CI (4.5-13.7). Eleven patients had a partial response to treatment (52, 4%), ten of them (90.9%) were alive, while the median survival was 27.9 months, SE 2.3 months 95% CI (23.5 -32.4). In three (14.3%) patients, a complete response to treatment was noted, of which three (100%) patients were alive. Cancer progression was noted in seven (33.3%) patients, two of them (28.6%) were alive, while the median survival was 27.9 months, SE 2.3 months 95% CI (23.5 -32.4). In analyzing six (28.6%) patients had AutoSCT, and 15 (71.4%) patients did not, due to low stem cell growth. Among patients, which didn't have AutoSCT 11 (73.3%) patients were alive, with a median survival of 30.4 months, a SE of 2.7 months of 95% ). When analyzing the causes of mortality, all patients indicated the cause of death from the progression of cancer. Summary/Conclusion: The analysis of the results using Brentuximab Vedotin showed good results in treatment of relapse and refractory forms of HL. In patients who failed to perform autologous stem cell transplantation, showed median survival of 30.4 months. This indicates the possibility of using the drug as an alternative to this procedure for the primary resistant form of the disease or further therapy options.

Background: Non-Hodgkin Lymphomas (NHL) effected organ of vision compose 8-12 % of all primary extranodal NHL, and may be the first and only sign of the disease. Aims: To estimate a therapy of patients with extranodal orbital lesion in our cancer center. Methods: Since 2014 to 2018 in our center treated 17 patients with extranodal damage to the orbit of the eyes. The age of patients ranged from 23 to 92 years, the average age of patients was 57 years. The number of men were 8 people, women -9. Unilateral orbital damage was registered in 15 patients, bilaterally in 2 patients. In 12 cases process localized in the anterior part of the orbit, in 5 -in the middle and deep parts of the orbit with the spread in the maxillary sinus. Clinical sings of NHL characterized with exophthalmos in varying degrees of severity, difficult reposition, displacement of the eyeball and restriction of its mobility, swelling of the eyelid. By all the observations: to 12 patients performed biopsy of the tumor, 4 patients underwent therapeutic and diagnostic orbitotomy by Killian, to 1 patient -eye orbit exentation. Histological variants: MALT-lymphomas -4 patients, Diffuse B-cell Lymphoma -8, Mantle Cell Lymphoma -2 and Follicular Lymphoma -2 patients. Results: All patients underwent 6 courses of chemotherapy according to the R-EPOCH protocol. Complete answer registered in 16 cases, partial answer in 1 of cases, and this patient received a course of radiation therapy on the affected area. Observation median was 3 years (15 month-5 years). Summary/Conclusion: Therefore, treating orbital NHL requires complex multidisciplinary approach, allowing determining the correct diagnosis and prescribing adequate treatment. Standart first line therapy achieved good results of relapse-free survival. Chemotherapy showed the same results as the combined treatment (chemotherapy and orbitotomy).

Background: Cancer being a lethal disease, delay in treatment may be fatal. International organizations have come up with useful guidelines for cancer management. Still the availability of resources, infrastructure, state health policy, COVID incidence and approach of healthcare professionals differ. This study aims to find out the perception and approaches of Indian oncologists -which might prove to be useful in nation specific delivery of cancer care during COVID Pandemic.Methods: After taking consent, a survey form was circulated online amongst oncologists (haemato/ radiation/ medical/ surgical) across the country and responses collected.Results: 79.2% oncologists represent private sector, 16.8% government sector. 50% oncologists were willing to postpone investigations for stable cancer patients. 42.6% willing to start treatment without knowing the COVID status, while 44.6% were against the idea and 12.9% were indecisive. 73% willing to perform surgery right away for operable nonemergency cases with a negative COVID status and rest 27 % willing to postpone surgery. Concurrent Chemoradiation (57%) was preferred over sequential approach (43%). Majority (53.5%) were comfortable prescribing chemotherapy via telemedicine. Asymptomatic COVID positive patients requiring chemotherapy 64.4% were willing to wait for the virus to resolve and then start therapy and 35.6% were suggesting some form of oral therapy and ongoing isolation. 89.1% preferred oral route if option present. 83.7 % preferred targeted therapy, 8.2% immunotherapy and rest went for other options. 93.1 % preferred day care chemotherapy during COVID and not admission. 61 % thought extended course of dexamethasone given as premedication during chemotherapy did not have a protective role for patients during COVID outbreak. Treatment initiation criteria in descending order -39.6% stage of the disease, 36.6 % performance status, 22.8% COVID status and for rest it was the cost. 91% oncologists thought nurses were at a higher risk of exposure to COVID infection than the doctors. 54.5% were not taking anti COVID prophylaxis.. Conclusions:Greater homogeneity in practice was noticed amongst oncologists of a developing nation during COVID outbreak. The above information might be useful in policy making.

The article is devoted to the history of the creation and development of the Oncohematology Department at the Kazakh Institute of Oncology and Radiology (KazIOR). For the first time, the authors talk about the development of oncohematology at KazIOR during the Soviet period in the USSR and the Kazakh SSR, and later -in independent Kazakhstan. They also describe the role of the institute directors and the contribution of the department heads at different stages of its history and share information about introducing new modern methods of diagnosing malignant lymphomas and new technologies for treating hemoblastosis. The authors also highlight the current topical problems of oncohematology and ways to solve them.

The article is devoted to the history of creation and development of the Oncohematology Department at the Kazakh Institute of Oncology and Radiology. For the first time, the authors talk about the development of oncohematology at the Kazakh Institute of Oncology and Radiology during the Soviet period in the USSR and the Kazakh SSR, and later – in independent Kazakhstan. They also describe the role of the institute directors and the contribution of the department heads at different stages of its history and share information about introducing new modern methods of diagnosing malignant lymphomas and new technologies for treating hemoblastosis. The authors also highlight the current topical problems of oncohematology and ways to solve them.